Form 4: Bio-Key International CEO Michael DePasquale Acquires 24,000 Shares of Common Stock

Michael DePasquale, CEO of Bio-Key International, acquired 24,000 shares of common stock on July 31, 2024, as part of a restricted stock grant.

Summary

• On July 31, 2024, Michael DePasquale, the CEO of Bio-Key International, acquired 24,000 shares of common stock.
• The acquisition was part of a restricted stock grant under the Issuer's 2023 Stock Incentive Plan.
• The shares vest in three equal annual installments, contingent upon DePasquale's continued employment with Bio-Key International.
• Following the transaction, DePasquale beneficially owns 44,573 shares of common stock.
• The holdings do not include options to purchase 348 shares and warrants to purchase 12,667 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CEO's stock acquisition suggests confidence in the company's future, but it's a routine grant rather than an open market purchase.

Positives

• The CEO's acquisition of shares demonstrates confidence in the company's future.
• The vesting schedule aligns the CEO's interests with the long-term performance of the company.

Future Outlook

The restricted stock vests over the next three years, subject to continued employment.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's prospects. This acquisition could be seen as a positive signal.

Stakeholder Impact

• The stock acquisition by the CEO could positively influence shareholder sentiment.
• Employees may view the CEO's increased stake as a sign of commitment to the company's success.

Key Dates

Keywords

BIO-KEY INTERNATIONAL, BKYI, Michael DePasquale, stock acquisition, restricted stock, Form 4, CEO, insider trading